Breadcrumb Navigation

Melanom: A phase I, first in human, two part, open-label clinical trial of intravenous administration of ctl-002 given as monotherapy and/or in combination with an anti-pd-1 checkpoint-inhibitor in subjects with advanced stage, relapsed/refractory solid tumors

Stadium/Indikation inkl. Kurzinfo

Melanom – 2nd line

Stadium III oder IV
(Auch mukosales oder Aderhaut-melanom)

Anti-GDF15, in Kombination mit anti-PD1

Kurztitel

CatalYm
CTL-002-001
NCT04725474

Offizieller Titel

A phase I, first in human, two part, open-label clinical trial of intravenous administration of ctl-002 given as monotherapy and/or in combination with an anti-pd-1 checkpoint-inhibitor in subjects with advanced stage, relapsed/refractory solid tumors

PI (Principal Investigator)

Prof. Reinhard Dummer

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Zuständige Ärztin

Simona Steinmann

Tel. +41 43 253 87 57

Behandelnder Fachbereich

Dermatologische Klinik